Sibel Cangi

Sibel Cangi

Auto-generated profile, based on publicly available information

Sibel Cangi

Department of Pathology, School of Medicine, Sanko University, Gaziantep, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSalih Serin
Salih Serin
HCHamdiye Celikaslan
Hamdiye Celikaslan
SCSibel Cangi
Sibel Cangi
Recep DokuyucuRecep Dokuyucu
Recep Dokuyucu
Polycystic ovary syndrome (PCOS) is characterized by insulin resistance, hyperandrogenism, oxidative stress, and disrupted folliculogenesis. The present study aimed to investigate whether combined alpha-lipoic acid (ALA) and vitamin D therapy exerts synergistic effects on metabolic, oxidative, endocrine, and histomorphological parameters in a letrozole-induced rat model of PCOS. Sixty female Wistar Albino rats were randomly divided into six groups: Control, PCOS, PCOS+Metformin (500 mg/kg/day), PCOS+Vitamin D (1000 IU/kg/day), PCOS + ALA (100 mg/kg/day), and PCOS + ALA+Vitamin D. PCOS was induced with letrozole (1 mg/kg/day) for 21 days, followed by 30 days of treatment. Fasting blood glucose (FBG), insulin, and HOMA-IR were assessed to evaluate metabolic status. Ovarian oxidative stress markers (MDA, SOD, CAT, GSH), serum hormonal parameters (testosterone, LH, FSH, LH/FSH ratio), and detailed histomorphometric analyses were performed. Statistical analyses included one-way and two-way ANOVA. Letrozole administration induced persistent diestrus, hyperandrogenemia, increased ovarian weight, elevated HOMA-IR (6.61 ± 1.18 vs. 2.24 ± 0.42, p < 0.001), and marked oxidative stress (MDA: 5.84 ± 0.72 vs. 2.31 ± 0.34 nmol/mg, p < 0.001). ALA and vitamin D monotherapies significantly improved metabolic, oxidative, and endocrine parameters compared with untreated PCOS rats (p < 0.05). The combination therapy group demonstrated the most pronounced improvements, with HOMA-IR (2.43 ± 0.47), MDA (2.52 ± 0.39 nmol/mg), testosterone (1.29 ± 0.27 ng/mL), and LH/FSH ratio (1.03 ± 0.19) values approaching control levels (all p < 0.01 vs. PCOS). Histologically, combined treatment markedly reduced cystic follicles and restored granulosa and theca thickness. Two-way ANOVA revealed significant interaction effects for HOMA-IR, MDA, testosterone, and LH/FSH ratio (p < 0.05). Combined ALA and vitamin D therapy produced enhanced improvements in insulin resistance, oxidative stress, endocrine imbalance, and ovarian morphology in experimental PCOS. Simultaneous targeting of mitochondrial redox dysfunction and endocrine–metabolic signaling pathways may represent a promising multidimensional therapeutic approach in PCOS.

5 May 2021
Verified
Book
Closed access
PDF file
EKEmine Kılınç
Emine Kılınç
SRSaime Ramadan
Saime Ramadan
SCSibel Cangi
Sibel Cangi
SŞSercan Şimşek
Sercan Şimşek
ABAbdulkadir Yasir Bahar
Abdulkadir Yasir Bahar
FPFatma Seher Pehlivan
Fatma Seher Pehlivan
Biz patologlar çalışma hayatımız boyunca belkide en çok lenfoid neoplazilere tanı koyarken zorluklar yaşıyoruz. Bu durum, bu neoplazilerin klonal olmalarına rağmen sınıflamalarında ve tanı konulma aşamalarında morfolojik, immünofenotipik, moleküler ve genetik gibi çok çeşitli parametrelerin gereksiniminden kaynaklanmaktadır. İsmini bildiğimiz ve tanısını koyduğumuz lenfoid neoplazilere zaman geçtikçe yenileri eklenmekte hatta provizyonel olarak kitaplara yeni yeni antiteler girmektedir. Tanı koymak bu durumda daha da zorluk kazanmaktadır. Biz de bu kitapta 31 kişiden oluşan bölüm yazarı meslektaşım ile sık gördüğümüz lenfoidneoplazilerin tanısını koymayı kolaylaştırmak, ayırıcı tanıları yapabilmek amacı ile yola çıkarak 30 bölümden oluşan hepimizin gereksinimi olan türkçe bir kitap oluşturduk.

27 October 2026 in İstanbul Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
BTBeril Balci Topuz
Beril Balci Topuz
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
SCSibel Cangi
Sibel Cangi
ÖYÖmer Aydın Yıldırım
Ömer Aydın Yıldırım
MYMustafa Yıldırım
Mustafa Yıldırım
Objective: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have transformed the treatment of metastatic renal cell carcinoma (mRCC), yet access limitations continue to shape real-world practice. This study evaluated the outcomes of second- and third-line systemic therapies administered after TKI failure within a single-center cohort.Materials and methods: This retrospective study included 50 patients with histologically confirmed mRCC treated between 2014 and 2024. Eligible patients had received at least one line of TKI therapy and subsequently received second-line nivolumab or axitinib. Survival outcomes were analyzed using Kaplan – Meier and log-rank tests.Results: The median age was 63 years; 76% were International Metastatic RCC Database Consortium intermediate-risk, and 82% had undergone nephrectomy. First-line therapy consisted of sunitinib (72%) or pazopanib (28%), with a median progression-free survival (PFS) of 7 months. In the second line, 40 patients (80%) received nivolumab and 10 (20%) axitinib. Median PFS and OS were 10 and 20 months for nivolumab vs. 4 and 5 months for axitinib (both p0.05). Five patients (four axitinib and one cabozantinib) were alive at the last follow-up.Conclusion: In this cohort, nivolumab was associated with longer PFS and OS compared to axitinib in the second-line setting after TKI failure, whereas axitinib and cabozantinib demonstrated similar outcomes in the third-line setting.